Topical formulations of chloroprocaine and methods of using same
AssigneeSintetica S.A.
InventorsAugusto Mitidieri, Elisabetta Donati, Clara Bianchi
Life of this patent
Estimating the term…
Abstract
Topical dosages and formulations of chloroprocaine and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly during ophthalmic procedures or in response to ophthalmic abrasions or trauma.
Claims36
1) A topical formulation for inducing local analgesia or anesthesia comprising:
- a) a therapeutically effective amount of chloroprocaine or a pharmaceutically acceptable salt thereof for inducing said local analgesia or anesthesia;
- b) one or more thickening agents;
- and
- c) water.
2) A topical gel formulation for inducing local analgesia or anesthesia comprising:
- a) a therapeutically effective amount of chloroprocaine or a pharmaceutically acceptable salt thereof for inducing said local analgesia or anesthesia;
- b) one or more thickening agents;
- and
- c) water.
3) An ophthalmic gel formulation for inducing local analgesia or anesthesia comprising:
- a) a therapeutically effective amount of chloroprocaine or a pharmaceutically acceptable salt thereof for inducing said local analgesia or anesthesia;
- b) one or more thickening agents;
- and
- c) water.
4) The formulation of any of the foregoing claims for inducing local analgesia or anesthesia without inducing significant irritation or toxicity.
5) The formulation of any of the foregoing claims for inducing local anesthesia or analgesia on the corneal surface during ocular surgery or in response to a corneal abrasion or trauma.
6) The formulation of any of the foregoing claims comprising from 2% to 4% by weight chloroprocaine or a pharmaceutically acceptable salt thereof.
7) The formulation of any of the foregoing claims comprising from 2% to 4% by weight chloroprocaine HCl or a pharmaceutically acceptable salt thereof.
8) The formulation of any of the foregoing claims comprising about 3% by weight chloroprocaine HCl.
9) The formulation of any of the foregoing claims wherein said thickening agent is selected from the group consisting of cellulose derivatives, natural gums, and inorganic compounds.
10) The formulation of any of the foregoing claims wherein said thickening agent is selected from the group consisting of methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, xanthan gum, guar gum, pectin, aluminum silicate, magnesium aluminum silicate, silica, and combinations thereof.
11) The formulation of any of the foregoing claims wherein said formulation comprises from 0.5% to 1.5% by weight hydroxyethyl cellulose.
12) The formulation of any of the foregoing claims wherein said formulation comprises from 0.6% to 1.4% by weight hydroxyethyl cellulose.
13) The formulation of any of the foregoing claims further comprising an acidic pH adjusting agent.
14) The formulation of any of the foregoing claims further comprising an acidic pH adjusting agent in an amount sufficient to impart a pH of from 2.8 to 3.8 to the formulation.
15) The formulation of any of the foregoing claims further comprising an acidic pH adjusting agent in an amount sufficient to impart a pH of from 3.0 to 4.0 to the formulation.
16) The formulation of any of the foregoing claims further comprising hydrochloric acid, lactic acid, citric acid and tartaric acid.
17) The formulation of any of the foregoing claims further comprising hydrochloric acid in an amount sufficient to impart a pH of from 2.8 to 4.0 to the formulation.
18) The formulation of any of the foregoing claims comprising hydroxyethyl cellulose in an amount sufficient to impart a viscosity of from 300 to 1500 mPas.
19) The formulation of any of the foregoing claims comprising:
- a) 3% by weight chloroprocaine HCl;
- b) 0.6% to 1.4% hydroxyethyl cellulose;
- c) hydrochloric acid q.s. to pH 2.8-4.0;
- and
- d) purified water q.s. to 100%.
20) The formulation of any of the foregoing claims comprising:
- a) 3% by weight chloroprocaine HCl;
- b) hydroxyethyl cellulose q.s. to 600-1400 mPas;
- c) hydrochloric acid q.s. to pH 2.8-4.0;
- and
- d) purified water q.s. to 100%.
21) The formulation of any of the foregoing claims wherein the formulation is sterile.
22) The formulation of any of the preceding claims wherein the water is water degassed by nitrogen bubbling.
23) The formulation of any of the foregoing claims having a viscosity of from 300 to 1500 mPas, as measured by a BrookField DV II+Pro Spindle 3 at 100 rpm, as described in section 2.2.10 of the European Pharmacopeia 2016 edition.
24) The formula of any of the foregoing claims in the form of a gel, lotion, ointment, paste or cream.
25) The formulation of any of the foregoing claims in the form of a monodose package comprising from 0.5 to 2 grams of gel.
26) The formulation of any of the foregoing claims which is clear or translucent.
27) The formulation of any of the foregoing claims capable of passage through a hydrophilic cartridge having a pore width of from 0.22 to 0.45 microns at 40° C. to 70° C. under pressure from air or nitrogen.
28) A method of manufacturing the formulation of any of the foregoing claims comprising admixing said chloroprocaine or pharmaceutically acceptable salt, said one or more thickening agents, a pH adjuster, and said water to make a formulation.
Dependencies are inferred from the claim text.